secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2026-05-13T12:15:06+00:00
Accession:  0001193125-26-220671
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma appoints Donn Casale as President effective June 1, 2026
-------------------------------------------------------------------

- Donn Casale, 53, most recently Chief Commercial Officer at Dynavax (acquired by Sanofi), joins as President.
- Casale will receive an annual base salary of $575,000 and target annual discretionary bonus of 45% of base.
- Stock option grant valued at ~$6M under 2020 Equity Incentive Plan; exercise price = grant date closing price.
- Option vests 25% after one year, then monthly over 36 months; subject to continued employment.
- He replaces Richard Lowenthal as President; Lowenthal remains CEO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312526220671/0001193125-26-220671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312526220671/d10320d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-220671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer